Natco Pharma today said it has launched fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets, used for the treatment of patients with chronic Hepatitis C virus (HCV) infection, it said in a filing to BSE.The company has launched the drug at a maximum retail price of Rs 17,500 for a bottle of 28 tablets, it added.Shares of Natco Pharma were trading at Rs 792.05 per scrip on BSE, down 1.43 per cent from the previous close.
from The Economic Times https://ift.tt/2z4oqDs
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment